Theriva Biologics, Inc. filed its quarterly report on Form 10-Q with the SEC on November 12, 2026, covering the three and nine months ended September 30, 2026, disclosing a continued operating loss alongside a significant reduction in operating expenses compared to the prior-year period.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $8,473 thousand as of September 30, 2026, down from $13,056 thousand at December 31, 2025, according to the filing.
  • Operating loss: Loss from operations for the nine months ended September 30, 2026 was $6,959 thousand, compared to $21,988 thousand for the same period in 2025, the company reported.
  • Q3 operating expenses: Total operating costs and expenses for the three months ended September 30, 2026 were $1,535 thousand, versus $4,440 thousand in Q3 2025.
  • Accumulated deficit: The accumulated deficit reached $365,442 thousand as of September 30, 2026, up from $358,710 thousand at December 31, 2025.
  • Shares outstanding: As of November 10, 2026, the registrant had 45,892,668 shares of common stock outstanding, $0.001 par value per share.
  • License revenue: The company disclosed $300 thousand in license revenue for the nine months ended September 30, 2026, compared to zero for the same period in 2025.
  • Total stockholders' equity: Total stockholders' equity was $10,753 thousand at September 30, 2026, compared to $15,383 thousand at December 31, 2025.

Theriva Biologics Reports Sharply Lower Expenses in Third Quarter 2026

Theriva Biologics, Inc. (NYSE American:TOVX), a Nevada-incorporated biopharmaceutical company headquartered in Rockville, MD, disclosed its unaudited condensed consolidated financial results for the quarterly period ended September 30, 2026. According to the filing, total operating costs and expenses for the three months ended September 30, 2026 were $1,535 thousand, a decrease from $4,440 thousand in the same quarter of 2025. General and administrative expenses for Q3 2026 were $923 thousand, compared to $1,889 thousand in Q3 2025, while research and development expenses were $612 thousand versus $2,551 thousand in the prior-year quarter.

For the nine-month period ended September 30, 2026, the company reported total operating costs and expenses of $7,259 thousand, down from $21,988 thousand for the nine months ended September 30, 2025. License revenue of $300 thousand was recognized in the nine-month period of 2026, with no equivalent revenue in the comparable 2025 period, the filing stated. The company's loss from operations for the nine months ended September 30, 2026 was $6,959 thousand.

On the balance sheet, total assets were $31,560 thousand at September 30, 2026, compared to $38,239 thousand at December 31, 2025. In-process research and development, a significant non-current asset, was listed at $18,956 thousand, down from $19,619 thousand at year-end 2025. Total liabilities were $20,807 thousand, including non-current contingent consideration of $8,978 thousand. The filing noted 45,921,478 shares issued and 45,892,668 shares outstanding at September 30, 2026, an increase from 35,717,159 issued and 35,688,350 outstanding at December 31, 2025. The company identified itself as a non-accelerated filer and smaller reporting company. Forward-looking statements in the filing are subject to the company's cautionary language and risk factors described in the report and in the 2025 Form 10-K.

What Was Disclosed

Theriva Biologics filed its Form 10-Q for the quarter ended September 30, 2026, reporting cash of $8,473 thousand, an operating loss of $6,959 thousand for the nine-month period, reduced total operating expenses versus the prior year, and an accumulated deficit of $365,442 thousand.